Company profile: SAB Biotherapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies and platform technologies, including SAB-142 for modulating the immune over-response in Type 1 Diabetes; SAB-176, a fully human polyclonal antibody for treatment and post-exposure prophylaxis of pandemic and seasonal influenza in high-risk patients; the DiversitAb platform for producing fully human, multi-targeted immunoglobulins without donors; and an Expanded Access Program.
Products and services
- DiversitAb Platform: Donor-independent platform technology for producing fully human, multi-targeted immunoglobulins without the need for human donors
- SAB-176: A fully-human polyclonal antibody for the treatment and post-exposure prophylaxis of pandemic and seasonal influenza, especially in high-risk patients
- SAB-142: Therapeutic candidate aimed at modifying the course of Type 1 Diabetes by targeting the immune system's over-reactive response
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SAB Biotherapeutics
Lyell
HQ: United States
Website
- Description: Provider of cellular immunotherapies and T-cell reprogramming for solid tumors, including CAR T-cell and TIL therapies. Offerings include Epi-R to generate stem-like T cells, Stim-R to optimize delivery of immune-activating molecules, and Rejuvenation Technology to reduce epigenetic age and enhance proliferation and antitumor activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lyell company profile →
Proclara Biosciences
HQ: United States
Website
- Description: Provider of a pioneering new approach to treating neurodegenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proclara Biosciences company profile →
Affiris
HQ: Austria
Website
- Description: Provider of tailor-made peptide vaccines and specific active immunotherapies for chronic diseases, including Alzheimer’s, Parkinson’s, atherosclerosis/hypercholesterolemia and hypertension. Portfolio includes AFFITOPE PD01/PD03 targeting alpha-synuclein, AFFITOPE AT04/AT06 targeting PCSK9 to lower LDL, mAB C6-17 for mutant huntingtin, and the SAIT modality.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affiris company profile →
Trubion
HQ: United States
Website
- Description: Provider of biopharmaceutical product candidates for autoimmune diseases and cancer, developing novel single-chain polypeptide proteins built with its SMIP custom drug assembly technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trubion company profile →
Atlab Pharma
HQ: France
Website
- Description: Provider of antibody-targeted anti-cancer drugs and radioimmunotherapy, developing monoclonal antibody-radioisotope conjugates to deliver tumor-specific radiation to cancer cells wherever they have disseminated in the body.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atlab Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SAB Biotherapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SAB Biotherapeutics
2.2 - Growth funds investing in similar companies to SAB Biotherapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SAB Biotherapeutics
4.2 - Public trading comparable groups for SAB Biotherapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →